Emrush Rexhaj1, Stefano F Rimoldi1, Lorenza Pratali2, Roman Brenner1, Daniela Andries3, Rodrigo Soria1, Carlos Salinas4, Mercedes Villena4, Catherine Romero4, Yves Allemann1, Alban Lovis3, Raphaël Heinzer3, Claudio Sartori5, Urs Scherrer6. 1. Department of Cardiology and Clinical Research, Inselspital, University of Bern, Bern, Switzerland. 2. Institute of Clinical Physiology, Pisa, Italy. 3. Center for Investigation and Research in Sleep, Lausanne-CHUV, Switzerland. 4. Instituto Boliviano de Biologia de Altura, La Paz, Bolivia. 5. Department of Cardiology and Clinical Research, Inselspital, University of Bern, Bern, Switzerland; Department of Internal Medicine, Lausanne-CHUV, Switzerland. 6. Department of Cardiology and Clinical Research, Inselspital, University of Bern, Bern, Switzerland; Facultad de Ciencias, Departamento de Biología, Universidad de Tarapacá, Arica, Chile. Electronic address: urs.scherrer2@insel.ch.
Abstract
BACKGROUND: Chronic mountain sickness (CMS) is often associated with vascular dysfunction, but the underlying mechanism is unknown. Sleep-disordered breathing (SDB) frequently occurs at high altitude. At low altitude, SDB causes vascular dysfunction. Moreover, in SDB, transient elevations of right-sided cardiac pressure may cause right-to-left shunting in the presence of a patent foramen ovale (PFO) and, in turn, further aggravate hypoxemia and pulmonary hypertension. We speculated that SDB and nocturnal hypoxemia are more pronounced in patients with CMS compared with healthy high-altitude dwellers, and are related to vascular dysfunction. METHODS: We performed overnight sleep recordings, and measured systemic and pulmonary artery pressure in 23 patients with CMS (mean ± SD age, 52.8 ± 9.8 y) and 12 healthy control subjects (47.8 ± 7.8 y) at 3,600 m. In a subgroup of 15 subjects with SDB, we assessed the presence of a PFO with transesophageal echocardiography. RESULTS: The major new findings were that in patients with CMS, (1) SDB and nocturnal hypoxemia was more severe (P < .01) than in control subjects (apnea-hypopnea index [AHI], 38.9 ± 25.5 vs 14.3 ± 7.8 number of events per hour [nb/h]; arterial oxygen saturation, 80.2% ± 3.6% vs 86.8% ± 1.7%, CMS vs control group), and (2) AHI was directly correlated with systemic blood pressure (r = 0.5216; P = .001) and pulmonary artery pressure (r = 0.4497; P = .024). PFO was associated with more severe SDB (AHI, 48.8 ± 24.7 vs 14.8 ± 7.3 nb/h; P = .013, PFO vs no PFO) and hypoxemia. CONCLUSIONS: SDB and nocturnal hypoxemia are more severe in patients with CMS than in control subjects and are associated with systemic and pulmonary vascular dysfunction. The presence of a PFO appeared to further aggravate SDB. Closure of the PFO may improve SDB, hypoxemia, and vascular dysfunction in patients with CMS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01182792; URL: www.clinicaltrials.gov.
BACKGROUND: Chronic mountain sickness (CMS) is often associated with vascular dysfunction, but the underlying mechanism is unknown. Sleep-disordered breathing (SDB) frequently occurs at high altitude. At low altitude, SDB causes vascular dysfunction. Moreover, in SDB, transient elevations of right-sided cardiac pressure may cause right-to-left shunting in the presence of a patent foramen ovale (PFO) and, in turn, further aggravate hypoxemia and pulmonary hypertension. We speculated that SDB and nocturnal hypoxemia are more pronounced in patients with CMS compared with healthy high-altitude dwellers, and are related to vascular dysfunction. METHODS: We performed overnight sleep recordings, and measured systemic and pulmonary artery pressure in 23 patients with CMS (mean ± SD age, 52.8 ± 9.8 y) and 12 healthy control subjects (47.8 ± 7.8 y) at 3,600 m. In a subgroup of 15 subjects with SDB, we assessed the presence of a PFO with transesophageal echocardiography. RESULTS: The major new findings were that in patients with CMS, (1) SDB and nocturnal hypoxemia was more severe (P < .01) than in control subjects (apnea-hypopnea index [AHI], 38.9 ± 25.5 vs 14.3 ± 7.8 number of events per hour [nb/h]; arterial oxygen saturation, 80.2% ± 3.6% vs 86.8% ± 1.7%, CMS vs control group), and (2) AHI was directly correlated with systemic blood pressure (r = 0.5216; P = .001) and pulmonary artery pressure (r = 0.4497; P = .024). PFO was associated with more severe SDB (AHI, 48.8 ± 24.7 vs 14.8 ± 7.3 nb/h; P = .013, PFO vs no PFO) and hypoxemia. CONCLUSIONS: SDB and nocturnal hypoxemia are more severe in patients with CMS than in control subjects and are associated with systemic and pulmonary vascular dysfunction. The presence of a PFO appeared to further aggravate SDB. Closure of the PFO may improve SDB, hypoxemia, and vascular dysfunction in patients with CMS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01182792; URL: www.clinicaltrials.gov.
Authors: Michael M Tymko; Justin S Lawley; Philip N Ainslie; Alexander B Hansen; Florian Hofstaetter; Simon Rainer; Sachin Amin; Gilbert Moralez; Christopher Gasho; Gustavo Vizcardo-Galindo; Daniela Bermudez; Francisco C Villafuerte; Christopher M Hearon Journal: Circ Res Date: 2020-04-09 Impact factor: 17.367
Authors: Stephan Pramsohler; Stefan Wimmer; Martin Kopp; Hannes Gatterer; Martin Faulhaber; Martin Burtscher; Nikolaus Cristoph Netzer Journal: BMC Neurosci Date: 2017-05-15 Impact factor: 3.288
Authors: Lu Tan; Taomei Li; Lian Luo; Xiaofang Xue; Fei Lei; Rong Ren; Ye Zhang; Jiaming He; Konrad E Bloch; Xiangdong Tang Journal: Nat Sci Sleep Date: 2022-09-01
Authors: Luu V Pham; Christopher Meinzen; Rafael S Arias; Noah G Schwartz; Adi Rattner; Catherine H Miele; Philip L Smith; Hartmut Schneider; J Jaime Miranda; Robert H Gilman; Vsevolod Y Polotsky; William Checkley; Alan R Schwartz Journal: High Alt Med Biol Date: 2017-03 Impact factor: 1.981